Wood D J, Heath A B
Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts, U.K.
Biologicals. 1992 Sep;20(3):203-11. doi: 10.1016/s1045-1056(05)80039-9.
The Second International Standard for anti-poliovirus sera types 1, 2 and 3 was established by the WHO Expert Committee on Biological Standardization in 1991 on the basis of an extensive collaborative study. Nine laboratories from eight countries participated and all used neutralizing antibody assays. The standard is a human serum pool which contains antibodies to all three poliovirus types and replaces the three previously established monovalent standards which were all hyperimmune monkey sera. The standard was assigned an activity of 25 IU of anti-poliovirus serum (type 1) human: 50 IU of anti-poliovirus serum (type 2) human; and 5 IU of anti-poliovirus serum (type 3) human. The study also showed significant interlaboratory differences in relative potency are observed when human sera are compared to hyperimmune monkey sera. It was therefore recommended that National laboratory references are established from human sera.
1991年，世界卫生组织生物标准化专家委员会在广泛合作研究的基础上，制定了第二种1、2和3型抗脊髓灰质炎病毒血清国际标准。来自八个国家的九个实验室参与其中，均采用中和抗体检测法。该标准为一种人血清混合液，含有针对所有三种脊髓灰质炎病毒类型的抗体，取代了之前制定的三种单价标准，这三种单价标准均为超免疫猴血清。该标准被赋予的活性为：抗脊髓灰质炎病毒血清（1型）人25国际单位；抗脊髓灰质炎病毒血清（2型）人50国际单位；抗脊髓灰质炎病毒血清（3型）人5国际单位。研究还表明，将人血清与超免疫猴血清进行比较时，实验室间相对效价存在显著差异。因此，建议从人血清中建立国家实验室参考标准。
